Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Peres LC, et al. Among authors: de avila g. Blood Adv. 2024 Jan 9;8(1):251-259. doi: 10.1182/bloodadvances.2023010894. Blood Adv. 2024. PMID: 37855718 Free PMC article.
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma.
Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Koomen DC, et al. Among authors: de avila g. J Proteome Res. 2021 Jun 4;20(6):3134-3149. doi: 10.1021/acs.jproteome.1c00022. Epub 2021 May 20. J Proteome Res. 2021. PMID: 34014671 Free PMC article.
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma.
Peres LC, Colin-Leitzinger CM, Teng M, Dutil J, Alugubelli RR, DeAvila G, Teer JK, Du D, Mo Q, Siegel EM, Hampton OA, Alsina M, Brayer J, Blue B, Baz R, Silva AS, Nishihori T, Shain KH, Gillis N. Peres LC, et al. Blood Adv. 2022 Jun 28;6(12):3767-3778. doi: 10.1182/bloodadvances.2021006652. Blood Adv. 2022. PMID: 35500227 Free PMC article.
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier C, Blue BJ, Brayer J, Chandrasekhar S, Grajales Cruz A, De Avila G, Elmariah H, Faramand R, Freeman C, Jain M, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Lee DH, et al. Among authors: de avila g. Blood Adv. 2023 Aug 22;7(16):4247-4257. doi: 10.1182/bloodadvances.2023009766. Blood Adv. 2023. PMID: 37307173 Free PMC article.
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Oswald LB, et al. Among authors: de avila g. Cancers (Basel). 2023 Sep 25;15(19):4711. doi: 10.3390/cancers15194711. Cancers (Basel). 2023. PMID: 37835405 Free PMC article.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Hashmi H, et al. Among authors: de avila g. Haematologica. 2024 May 1;109(5):1514-1524. doi: 10.3324/haematol.2023.283888. Haematologica. 2024. PMID: 37855036 Free PMC article.
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda Puglianini O, Grajales Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Akhtar OS, et al. Among authors: de avila g. Transplant Cell Ther. 2024 Mar;30(3):283.e1-283.e10. doi: 10.1016/j.jtct.2023.12.010. Epub 2023 Dec 18. Transplant Cell Ther. 2024. PMID: 38123069
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: de avila g. Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945. Blood. 2025. PMID: 39365257
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. Sudalagunta PR, et al. Cancer Res. 2025 Jan 15;85(2):378-398. doi: 10.1158/0008-5472.CAN-24-0886. Cancer Res. 2025. PMID: 39476082 Free PMC article.
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes.
Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Freeman CL, et al. Among authors: de avila g. Blood. 2024 Dec 9:blood.2024024965. doi: 10.1182/blood.2024024965. Online ahead of print. Blood. 2024. PMID: 39652773
25 results